Maria Kjær Terapi ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  14.1% 18.4% 15.8% 13.0% 18.3%  
Credit score (0-100)  17 7 11 17 7  
Credit rating  BB B BB BB B  
Credit limit (kDKK)  0.0 -0.0 0.0 -0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -1.0 -17.9 45.3 -34.3 1.4  
EBITDA  -1.0 -17.9 45.3 -34.3 1.4  
EBIT  -1.0 -17.9 45.3 -34.3 1.4  
Pre-tax profit (PTP)  -2.0 -19.0 42.8 -35.8 -0.1  
Net earnings  -2.0 -15.0 33.4 -27.8 -0.1  
Pre-tax profit without non-rec. items  -2.0 -19.0 42.8 -35.8 -0.1  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  -2.0 -16.3 34.8 7.0 6.9  
Interest-bearing liabilities  3.0 13.3 17.4 22.7 4.0  
Balance sheet total (assets)  8.0 5.1 63.9 32.9 15.4  

Net Debt  -5.0 12.3 -46.5 -1.9 -8.4  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -1.0 -17.9 45.3 -34.3 1.4  
Gross profit growth  0.0% -1,685.7% 0.0% 0.0% 0.0%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  8 5 64 33 15  
Balance sheet change%  0.0% -36.5% 1,157.1% -48.4% -53.3%  
Added value  -1.0 -17.9 45.3 -34.3 1.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -1.0 -2.0 1.0 -1.0 1.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -10.0% -113.8% 106.2% -70.2% 5.8%  
ROI %  -33.3% -218.4% 138.2% -82.8% 6.9%  
ROE %  -25.0% -228.8% 167.3% -132.7% -1.4%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  -20.0% -76.2% 54.6% 21.4% 45.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  500.0% -68.7% -102.7% 5.5% -602.2%  
Gearing %  -150.0% -81.9% 49.8% 322.8% 58.0%  
Net interest  0 0 0 0 0  
Financing costs %  66.7% 13.5% 16.2% 9.0% 11.2%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.8 0.2 2.2 1.3 1.8  
Current Ratio  0.8 0.2 2.2 1.3 1.8  
Cash and cash equivalent  8.0 1.1 63.9 24.6 12.4  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -2.0 -16.3 34.8 7.0 6.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  -1 -18 45 -34 1  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -1 -18 45 -34 1  
EBIT / employee  -1 -18 45 -34 1  
Net earnings / employee  -2 -15 33 -28 -0